Mesoblast Ltd. is a pharmaceutical company based in Australia that specializes in developing and commercializing innovative allogeneic cellular medicines for treating complex diseases. With a risk rating score of 26.1, the company is categorized as having a medium risk assessment. Mesoblast's portfolio includes Phase 3 product candidates such as remestemcel-L, designed to address conditions like steroid-refractory acute graft versus host disease (SR-aGVHD) and acute respiratory distress syndrome (ARDS). The company's focus on ESG principles makes it a promising player in the pharmaceutical industry.